Literature DB >> 11277943

High affinity binding of paclitaxel to human serum albumin.

K Paál1, J Müller, L Hegedûs.   

Abstract

Paclitaxel, a very potent antitumor agent is a hydrophobic molecule with low aqueous solubility. Its currently used formula (Taxol) contains the drug in a 1 : 1 (v/v) mixture of ethanol and Cremophor EL. To minimize vehicle-related toxicity, we developed a novel, water-soluble formulation in which paclitaxel is bound noncovalently to human serum albumin. For this purpose, studies of the paclitaxel-albumin binding equilibrium were performed. Paclitaxel dissolved in ethanol was added to the aqueous solution of human serum albumin. Precipitated paclitaxel was removed and unbound drug was separated by ultrafiltration. Paclitaxel concentration was measured by RP-HPLC. Binding data were evaluated based both on the Scatchard plot and the general binding equation describing binding equilibria with the stepwise stoichiometric binding constants. The Scatchard plot was found to be curvilinear with a slight positive slope of the final part. Parameters of high affinity specific binding were determined from the initial part of the curve (nsp = 1.3 and Ksp = 1.7 x 10(6) M(-1)). Stoichiometric binding constants were estimated by fitting the general binding equation to the experimental data (K1 = 2.4 x 10(6) M(-1) and K2 = 1.0 x 10(5) M(-1)). Saturation of the protein with paclitaxel, similarly to other ligands of albumin, could not be reached. The greatest observed value of r (number of paclitaxel molecules bound to one albumin molecule) was 6.6.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277943     DOI: 10.1046/j.1432-1327.2001.02107.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  39 in total

1.  Calculation of normalized drug concentrations in the presence of altered plasma protein binding.

Authors:  Florin Marcel Musteata
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel.

Authors:  Yixian Huang; Jianqin Lu; Xiang Gao; Jiang Li; Wenchen Zhao; Ming Sun; Donna Beer Stolz; Raman Venkataramanan; Lisa Cencia Rohan; Song Li
Journal:  Bioconjug Chem       Date:  2012-06-20       Impact factor: 4.774

3.  HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy.

Authors:  Qimeng Quan; Jin Xie; Haokao Gao; Min Yang; Fan Zhang; Gang Liu; Xin Lin; Andrew Wang; Henry S Eden; Seulki Lee; Guixiang Zhang; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2011-08-22       Impact factor: 4.939

4.  Kinetic analysis of nanoparticulate polyelectrolyte complex interactions with endothelial cells.

Authors:  Sean M Hartig; Rachel R Greene; Gianluca Carlesso; James N Higginbotham; Wasif N Khan; Ales Prokop; Jeffrey M Davidson
Journal:  Biomaterials       Date:  2007-05-03       Impact factor: 12.479

5.  Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Authors:  Feihu Wang; Michael Porter; Alexandros Konstantopoulos; Pengcheng Zhang; Honggang Cui
Journal:  J Control Release       Date:  2017-09-25       Impact factor: 9.776

6.  Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.

Authors:  Elvin Blanco; Takafumi Sangai; Suhong Wu; Angela Hsiao; Guillermo U Ruiz-Esparza; Carlos A Gonzalez-Delgado; Francisca E Cara; Sergio Granados-Principal; Kurt W Evans; Argun Akcakanat; Ying Wang; Kim-Anh Do; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Ther       Date:  2014-02-26       Impact factor: 11.454

Review 7.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

8.  Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery.

Authors:  Jonathan G Mehtala; Chris Kulczar; Monika Lavan; Gregory Knipp; Alexander Wei
Journal:  Bioconjug Chem       Date:  2015-05-08       Impact factor: 4.774

9.  Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles.

Authors:  Dongmei Zhao; Xiuhua Zhao; Yuangang Zu; Jialei Li; Yu Zhang; Ru Jiang; Zhonghua Zhang
Journal:  Int J Nanomedicine       Date:  2010-09-20

Review 10.  Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Federica Tomao; Silverio Tomao
Journal:  Int J Nanomedicine       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.